The efficacy of gabapentin in children of partial seizures and the blood levels

Brain and Development

Volumn 36, Issue 3, 2014, Pages 194-202

  Nonoda, Yutaka ^a   Iwasaki, Toshiyuki ^a   Ishii, Masahiro ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antiepileptic drug; Localization related epilepsy; Optimal range; Paroxysmal strength and length; Response ratio

Indexed keywords

ANTIEPILEPTIC DRUG; LOCALIZATION RELATED EPILEPSY; OPTIMAL RANGE; PAROXYSMAL STRENGTH AND LENGTH; RESPONSE RATIO;

ADOLESCENT; AGE FACTORS; AMINES; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; CYCLOHEXANECARBOXYLIC ACIDS; EPILEPSIES, PARTIAL; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; PROSPECTIVE STUDIES; SEIZURES; SEX FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84893845065     PISSN: 03877604     EISSN: 18727131     Source Type: Journal    
DOI: 10.1016/j.braindev.2013.04.006     Document Type: Article

References (31)

1. Hauer J.M., Wical B.S., Charnas L. Gabapentin successfully manages chronic unexplained irritability in children with severe neurologic impairment. Pediatrics 2007, 119:e519-e522.
2. Low A.K., Ward K., Wines A.P. Pediatric complex regional pain syndrome. J Pediatr Orthop 2007, 27:567-572.
3. Daoud A.S., Bataineh H., Otoom S., Abdul-Zahra E. The effect of vigabatrin, lamotrigine and gabapentin of the fertility, weights, sex hormones and biochemical profiles of male rats. Neuro Endocrinol Lett 2004, 25:178-183.
4. Jallon P., Picard F. Bodyweight gain and anticonvulsants. A comparative review. Drug safety 2001, 24:969-978.
5. Verrotti A., Manco R., Matricardi S., Franzoni E., Chiarelli F. Antiepileptic drugs and visual function. Pediatr Neurol 2007, 36:353-360.
6. Middleton O. Suicide by gabapentin overdose. J Forensic Sci 2011, 56:1373-1375.
7. Hellwig T.R., Hammerquist R., Termaat J. Withdrawal symptoms after gabapentin discontinuation. Am J Health Syst Pharm 2010, 67:910-912.
8. Chen C., Cowles V.E., Hou E. Pharmacokinetics of gabapentin in a novel gastric-retentive extended-release formulation: comparison with an immediate-release formulation and effect of dose escalation and food. J Clin Pharmacol 2011, 51:346-358.
9. Lal R., Sukbuntherng J., Luo W., Chen D., Vu A., Tovera J., et al. Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers. Clin Ther 2009, 31:1776-1786.
10. Governo R.J., Morris P.G., Marsden C.A., Chapman V. Gabapentin evoked changes in functional activity in nociceptive regions in the brain of the anaesthetized rat: an fMRI study. Br J Pharmacol 2008, 153:1558-1567.
11. Hwang H., Kim K.J. New antiepileptic drugs in pediatric epilepsy. Brain Dev 2008, 30:549-555.
12. 2δ ligands: novel modulators of neurotransmission. Trends Pharmacol Sci 2007, 28:75-82.
13. Sills G.J. The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol 2006, 6:108-113.
14. Tallian K.B., Nahata M.C., Lo W., Tsao C.Y. Pharmacokinetics of gabapentin in paediatric patients with uncontrolled seizures. J Clin Pharm Ther 2004, 29:511-515.
15. Cilio M.R., Bolanos A.R., Liu Z., Schmid R., Yang Y., Stafstrom C.E., et al. Anticonvulsant action and long-term effects of gabapentin in the immature brain. Neuropharmacology 2001, 40:139-147.
16. Wallace S.J. Newer antiepileptic drugs: advantages and disadvantages. Brain Dev 2001, 23:277-283.
17. Perucca E. Clinical pharmacology and therapeutic use of the new antiepileptic drugs. Fundam Clin Pharmacol 2001, 15:405-417.
18. Ebrahimzadeh H., Yamini Y., Firozjaei H.A., Kamarei F., Tavassoli N., Rouini M.R. Hollow fiber-based liquid phase microextraction combined with high-performance liquid chromatography for the analysis of gabapentin in biological samples. Anal Chim Acta 2010, 665:221-226.
19. Kolocouri F., Dotsikas Y., Loukas Y.L. Dried plasma spots as an alternative sample collection technique for the quantitative LC-MS/MS determination of gabapentin. Anal Bioanal Chem 2010, 398:1339-1347.
20. Wattananat T., Akarawut W. Validated LC-MS-MS method for the determination of gabapentin in human plasma: application to a bioequivalence study. J Chromatogr Sci 2009, 47:868-871.
21. Sagirli O., Cetin S.M., Onal A. Determination of gabapentin in human plasma and urine by high-performance liquid chromatography with UV-vis detection. J Pharm Biomed Anal 2006, 42:618-624.
22. Ji H.Y., Jeong D.W., Kim Y.H., Kim H.H., Yoon Y.S., Lee K.C., et al. Determination of gabapentin in human plasma using hydrophilic interaction liquid chromatography with tandem mass spectrometry. Rapid Commun Mass Spectrom 2006, 20:2127-2132.
23. Borrey D.C., Godderis K.O., Engelrelst V.I., Bernard D.R., Langlois M.R. Quantitative determination of vigabatrin and gabapentin in human serum by gas chromatography-mass spectrometry. Clin Chim Acta 2005, 354:147-151.
24. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006, 61:246-255.
25. Gatti G., Ferrari A.R., Guerrini R., Bonanni P., Bonomi I., Perucca E. Plasma gabapentin levels in children with epilepsy: influence of age, relationship with dosage, and preliminary observations on correlation with clinical response. Ther Drug Monit 2003, 25:54-60.
26. Muscas G.C., Chiroli S., Luceri F., Mastio M.D., Balestrieri F., Arnetoli G. Conversion from thrice daily to twice daily administration of gabapentin (GBP) in partial epilepsy: analysis of clinical efficacy and plasma levels. Seizure 2000, 9:47-50.
27. Anhut H., Ashman P., Feuerstein T.J., Sauermann W., Saunders M., Schmidt B. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. The international gabapentin study group. Epilepsia 1994, 35:795-801.
28. Leiderman D.B. Gabapentin as add-on therapy for refractory partial epilepsy: results of five placebo-controlled trials. Epilepsia 1994, 35:S74-S76.
29. Marson A.G., Kadir Z.A., Hutton J.L., Chadwick D.W. The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 1997, 38:859-880.
30. Appleton R., Fichtner K., LaMoreaux L., Alexander J., Halsall G., Murray G., et al. Gabapentin as add-on therapy in children with refractory partial seizures: a 12-week, multicentre, double-blind, placebo-controlled study. Epilepsia 1999, 40:1147-1154.
31. Öhman I., Vitols S., Tomson T. Pharmacokinetics of gabapentin during delivery, in the neonatal period, and lactation: does a fetal accumulation occur during pregnancy?. Epilepsia 2005, 46:1621-1624.